Biomarker Guided Treatment in Gynaecological Cancer
Status:
Recruiting
Trial end date:
2033-12-01
Target enrollment:
Participant gender:
Summary
MoMaTEC2 aims to test, in clinically oriented studies, the applicability of already
identified and promising molecular biomarkers, to promote individualisation of treatment for
patients with endometrial cancer. Predominantly, but not exclusively, such biomarkers have
shown to be interesting in retrospective analysis of our large prospectively collected
MoMaTEC1 series.
Part 1: Performance of a phase 4 implementation trial for optimised stratification of
surgical treatment, specifically the performance of (para-aortic and pelvic) lymphadenectomy
guided by validated biomarkers.
Part 2: Performance of a phase 2b clinical biomarker study to evaluate the predictive
potential of the biomarker stathmin for taxane treatment response in endometrial and ovarian
cancer. In this study stathmin will be used as integrated biomarker.